Cargando…
Modulating the Blood–Brain Barrier: A Comprehensive Review
The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618722/ https://www.ncbi.nlm.nih.gov/pubmed/34834395 http://dx.doi.org/10.3390/pharmaceutics13111980 |
_version_ | 1784604816330194944 |
---|---|
author | Whelan, Rory Hargaden, Grainne C. Knox, Andrew J. S. |
author_facet | Whelan, Rory Hargaden, Grainne C. Knox, Andrew J. S. |
author_sort | Whelan, Rory |
collection | PubMed |
description | The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area. Naturally, the field has garnered a great deal of attention, leading to a vast and diverse range of BBB modulators. In this review, we summarise and compare the various classes of BBB modulators developed over the last five decades—their recent advancements, advantages and disadvantages, while providing some insight into their future as BBB modulators. |
format | Online Article Text |
id | pubmed-8618722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86187222021-11-27 Modulating the Blood–Brain Barrier: A Comprehensive Review Whelan, Rory Hargaden, Grainne C. Knox, Andrew J. S. Pharmaceutics Review The highly secure blood–brain barrier (BBB) restricts drug access to the brain, limiting the molecular toolkit for treating central nervous system (CNS) diseases to small, lipophilic drugs. Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area. Naturally, the field has garnered a great deal of attention, leading to a vast and diverse range of BBB modulators. In this review, we summarise and compare the various classes of BBB modulators developed over the last five decades—their recent advancements, advantages and disadvantages, while providing some insight into their future as BBB modulators. MDPI 2021-11-22 /pmc/articles/PMC8618722/ /pubmed/34834395 http://dx.doi.org/10.3390/pharmaceutics13111980 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Whelan, Rory Hargaden, Grainne C. Knox, Andrew J. S. Modulating the Blood–Brain Barrier: A Comprehensive Review |
title | Modulating the Blood–Brain Barrier: A Comprehensive Review |
title_full | Modulating the Blood–Brain Barrier: A Comprehensive Review |
title_fullStr | Modulating the Blood–Brain Barrier: A Comprehensive Review |
title_full_unstemmed | Modulating the Blood–Brain Barrier: A Comprehensive Review |
title_short | Modulating the Blood–Brain Barrier: A Comprehensive Review |
title_sort | modulating the blood–brain barrier: a comprehensive review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618722/ https://www.ncbi.nlm.nih.gov/pubmed/34834395 http://dx.doi.org/10.3390/pharmaceutics13111980 |
work_keys_str_mv | AT whelanrory modulatingthebloodbrainbarrieracomprehensivereview AT hargadengrainnec modulatingthebloodbrainbarrieracomprehensivereview AT knoxandrewjs modulatingthebloodbrainbarrieracomprehensivereview |